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Résumé 
Objectif principal Il n’est pas démontré que les interventions visant à maîtriser voire 
modérer la médicamentation de patients atteints d’hypertension peuvent améliorer 
leur gestion de la maladie. Cette revue systématique propose d’évaluer les 
programmes de gestion contrôlée de la médicamentation pour l’hypertension, en 
s’appuyant sur la mesure de l’observance des traitements par les patients (CMGM).  
Design Revue systématique. 
Sources de données MEDLINE, EMBASE, CENTRAL, résumés de conférences 
internationales sur l’hypertension et bibliographies des articles pertinents. 
Méthodes Des essais contrôlés randomisés (ECR) et des études observationnelles 
(EO) ont été évalués par 2 réviseurs indépendants. L’évaluation de la qualité (de ce 
matériel) a été réalisée avec l’aide de l’outil de Cochrane de mesure du risque de 
biais, et a été estimée selon une échelle à quatre niveaux de qualité Une synthèse 
narrative des données a été effectuée en raison de l'hétérogénéité importante des 
études. 
Résultats 13 études (8 ECR, 5 EO) de 2150 patients hypertendus ont été prises en 
compte. Parmi elles, 5 études de CMGM avec l’utilisation de dispositifs électroniques 
comme seule intervention ont relevé une diminution de la tension artérielle (TA), qui 
pourrait cependant être expliquée par les biais de mesure. L’amélioration à court 
terme de la TA sous CMGM dans les interventions complexes a été révélée dans 4 
études à qualité faible ou modérée. Dans 4 autres études sur les soins intégrés de 
qualité supérieure, il n'a pas été possible de distinguer l'impact de la composante 
CMGM, celle-ci pouvant être compromise par des traitements médicamenteux. 
L’ensemble des études semble par ailleurs montrer qu’un feed-back régulier au 
médecin traitant peut être un élément essentiel d’efficacité des traitements CMGM, et 
peut être facilement assuré par une infirmière ou un pharmacien, grâce à des outils de 
communication appropriés. 
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Conclusions Aucune preuve convaincante de l'efficacité des traitements CMGM 
comme technologie de la santé n’a été établie en raison de designs non-optimaux des 
études identifiées et des ualités méthodologiques insatisfaisantes de celles-ci. Les 
recherches futures devraient : suivre les normes de qualité approuvées et les 
recommandations cliniques actuelles pour le traitement de l'hypertension, inclure des 
groupes spécifiques de patients avec des problèmes d’attachement aux traitements,  et 
considérer les résultats cliniques et économiques de l'organisation de soins ainsi que 
les observations rapportées par les patients. 
Mots-clés : hypertension, des médicaments antihypertensifs, attachement des patients 
au traitement medicamentif, surveillance électronique, nombre de comprimés, revue 
systématique, évaluation des technologies de la santé, évaluation des soins intégrés 
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Abstract 
Objective Whether interventions including measurement and correction of patients’ 
attitude to antihypertensive medication can improve hypertension management is 
unclear. The review aims to determine the effectiveness of patient compliance 
measurement-guided medication management (CMGM) programs in essential 
hypertension.   
Design Systematic review. 
Data sources MEDLINE, EMBASE, CENTRAL, hypertension meetings abstracts, 
and bibliographies of identified articles.   
Methods Randomized controlled trials (RCT) and observational studies (OS) were 
assessed by 2 reviewers independently. Quality assessment was performed with the 
Cochrane risk of bias tool and evaluated in a four-point continuum. A narrative data 
synthesis was performed due to significant heterogeneity among studies. 
Results 13 studies (8 RCT, 5 OS) involving 2150 hypertensives were included. Five 
trials of CMGM with electronic devices as a sole intervention suggested decrease in 
blood pressure (BP) but the result may have been due to bias. Short-term BP 
improvement under CMGM in complex interventions was revealed in 4 studies of 
low-to-moderate quality. In 4 integrated care studies of higher quality the impact of 
CMGM component was not possible to distil and may be compromised by 
medication regimens. Regular feedback to the treating physician seems to be an 
essential component of CMGM and may be effectively mediated by a nurse or a 
pharmacist and via telecommunication.  
Conclusions No convincing evidence for the effectiveness of CMGM as a health 
technology was found due to non-optimal study designs and methodological quality. 
Future research should follow accepted quality standards and current guidelines for 
the treatment of hypertension, include specific groups of patients with compliance 
problems and consider clinical, economic, patient-reported and organizational 
outcomes. 
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Introduction 
Patients’ non-compliance with prescribed medication regimens is common 
worldwide and poses a significant clinical practice problem.[1] It can influence 
effectiveness, safety and cost-effectiveness of therapeutic interventions via 
deterioration of patients’ health outcomes, the need for additional consultations and 
other services, the use of extra drugs, avoidable hospital admissions and increases in 
direct and indirect costs of management.[2,3] A recent meta-analysis revealed that the 
risk of mortality for those who were compliant with drug therapy was about half that 
of participants who were not.[4] 
High blood pressure (BP) or essential hypertension is the most prevalent 
cardiovascular disorder worldwide, and simultaneously a major risk factor for 
cardiovascular morbidity and mortality with their important socioeconomic burden. [5] 
Evidence from randomized controlled trials (RCT) has clearly shown that effective 
drug treatment of hypertension reduces the risk of cardiovascular morbidity and 
mortality, mainly through improved BP control.[6] Nevertheless, there is ongoing 
concern that the benefits demonstrated in RCTs of antihypertensive drug treatment 
are not realized in everyday clinical practice.[7,8]  BP control is still far from optimal 
worldwide, and non-compliance has been suggested as a major reason for treatment 
failure. [9,10,11] 
Although the gold standard in patient compliance evaluation is not yet 
established, an important progress in concepts and techniques in this field has been 
reached during the last two decades. Electronic pill box monitors or electronic 
compliance monitoring devices (ECMDs), which enable monitoring of the daily 
dosing by recording the time of each opening of the pill container or taking a tablet 
out of a blister pack, became available in some research and clinical settings. They 
have markedly advanced our knowledge of medication-taking behaviour and its risk 
factors.[11,12] At the same time, the new key paradigm of understanding and 
management of medication compliance or adherence was introduced. According to 
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that, the prescription is really a contract between the patient and the physician and 
both are really responsible for the medication-taking; hence, they should interact on 
the matter in the process of treatment, in concordance with the contract.[13] Such 
direct compliance management per se (which can include measurement, feedback and 
counselling)  may be considered and used as an active component of hypertension 
treatment programs to improve their outcomes.  This novel approach has been 
referred to as “compliance measurement-guided (medication) management (CMGM) 
programs”.[14] 
Many other approaches for indirect correction of patient compliance with 
medication during hypertension management have been suggested, and some of them 
were evaluated in a systematic manner. The Cochrane review by Schroeder et al [15] 
finalized in 2004 concluded that, among many approaches tested, only reducing the 
number of daily doses appears to be effective in increasing adherence, but not BP 
control. The authors claim motivational strategies and complex interventions appear 
promising which should be addressed in future studies and reviews.  The most 
comprehensive systematic review by Haynes et al[16] on interventions for enhancing 
medication adherence  in chronic diseases  (including hypertension) declared current 
methods of improving adherence are mostly complex,  but  not very effective. It is 
concluded high priority should be given to fundamental and applied research 
concerning innovations to assist patients to follow medication prescriptions for long-
term medical disorders.  
In general, there is growing, but still insufficient evidence as to how care for 
hypertensive patients should be organized and delivered in the community to help 
improve BP. A recently updated Cochrane systematic review provided a partial 
answer to this question.[17] However, although the authors offered general conclusions 
about the usefulness of “an organized system of regular follow-up and review of 
hypertensive patients” where antihypertensive drug therapy should be implemented 
by means of a “vigorous stepped care approach,” they otherwise failed to focus on 
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patient compliance issues.  Another recent and more specific systematic review of 
team-based care interventions in hypertension management involving nurses or 
pharmacists revealed that such strategies are effective to improve BP control.[18] In 
this meta-analysis, several individual components, including medication compliance 
assessment, were indirectly associated with improvement in BP.   
Different concepts and designs of integrated care (pharmaceutical care, nurse-
led care, team-based care) have been suggested to improve effectiveness of chronic 
disease management.[16-18] Identification and systematic evaluation of essential and 
most efficacious components of proposed integrated care approaches is necessary, 
taking into account the high resource-consuming nature of such programs, problems 
of their transferability and feasibility in different health care systems and diverse 
populations. Further research evaluating the role of specific components of complex 
interventions aimed to improve BP control is therefore promising. However, among 
the systematic reviews published in recent years and looking at different adherence-
enhancing approaches[15-20] no one, up to our best knowledge, primarily and 
comprehensively addressed effectiveness of immediate compliance management 
(measurement augmented by feedback to stakeholders and counselling) as an active 
intervention or health technology.  
The primary objective of this review was to assess the evidence of the 
effectiveness of CMGM interventions in treating adults with essential hypertension.   
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Methods 
Compliance operational definitions 
In this review the terms “patient compliance” and “patient (medication) 
adherence” were considered as synonyms.  Under these terms we mean “the extent to 
which a patient’s behaviour, with respect to taking medication, corresponds with 
agreed recommendations from healthcare providers”.[21] We therefore assumed (but 
do not limit to) the following approaches of compliance measures: subjective 
methods (e.g. patient interview, patient diaries, patient self-questionnaire); direct 
methods (e.g. analysis of biomarkers in bodily fluids); indirect methods (e.g., 
physiologic markers, pill counts, pharmacy claim data (prescription refills) and 
ECMDs.[22] We were ready to consider any compliance expressions, including 
binomial (Yes or No), ordinal (full, partly, non-compliance) or continuous (e.g., % of 
the total dose prescribed in a given period of time) compliance measures. The scope 
of the review was CMGM or  immediate compliance management as an intervention, 
under which we implied several components: compliance measurement (monitoring),  
providing  a feedback to the patient (and/or to his/her physician) on his/her dosing 
history, and individual counselling provided by a health professional and tailored by 
contemporary medication taking behaviour.  
Criteria for considering studies for this review 
PICOS (population – intervention - comparators – outcomes – study design) 
paradigm of the systematic review is briefly summarized in Appendix 1.  
The population of interest was composed of adult patients (aged 18 years or 
over) with verified essential (primary) hypertension of any stage / grade eligible for 
BP lowering drug treatment (treated or not  previously treated) in a primary care, 
outpatient or other community setting. Studies of non-pharmacological treatment 
were not included. 
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We considered published studies of any duration with CMGM as intervention 
designed to estimate and therefore enhance patient compliance with a medication 
regimen with the final aim to improve outcomes in hypertension. At least the 
compliance measurement component must be included in a CMGM program and may 
be addicted with feedback and counselling.  
Different strategies or combinations of components of CMGM may be 
compared in one study or a CMGM intervention may be compared with no such 
intervention or “usual care” (UC).   Studies with different comparators (e.g. with 
identical compliance management in study arms) were excluded.  
Studies were included if they reported at least one of the next groups  of 
hypertension management outcomes:  mortality (cardiovascular, non-cardiovascular, 
total); morbidity (cardiovascular – stroke,  myocardial infarction;  non-
cardiovascular); BP changes / control which we supposed may be expressed via (1) 
mean systolic BP (SBP)  and/or mean diastolic BP (DBP) values; (2) mean SBP 
(mean DBP) changes (delta); (3) reaching pre-specified BP threshold  (according to a 
particular study); changes in structure and function of target organs (the heart, kidney, 
brain, vessels); rate and patterns of adverse reactions (led or not led to withdrawals); 
organizational outcomes: important features of management  (rate of hospital 
admissions, number of visits to general  practitioners,  consultant physicians, any 
other caregiver services, medication regimens changes, etc.); humanistic or patient-
reported ones (health-related quality of life, patient satisfaction, patient preferences); 
economic outcomes. As the secondary outcome, we were ready to analyze 
compliance with medication per se (including any definition of compliance / 
adherence and noting how this was defined and measured in each study).  However, 
trials reported compliance data only as pre-specified primary outcomes were not 
included.  
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The following study designs were considered:  RCTs (patient-randomized, 
cluster-randomized or quasi-randomized trials);  cohort studies with or without 
controls (matched, unmatched, historic or internal). Secondary publications and 
interim reports were excluded. 
Search methods for identification of studies 
Original studies eligible for inclusion in the review were identified by an all-
language search of all articles in MEDLINE (1980 to July 2010), EMBASE (1980 to 
July 2010), and the Cochrane Central Register of Controlled Trials (CENTRAL) 
(1980 to July 2010) via OVID platform.  
A systematic search strategy was applied with use of a series of topic terms 
including hypertension/BP, patient compliance/adherence, reflecting pre-specified 
CMGM components and study designs (The principal strategy which was used for 
MEDLINE search is in Appendix 2). As a component of the search strategy, a 
previously validated original research string of terms was used.[23] Similar thinking 
was used also for search of EMBASE and CENTRAL databases. Articles published 
before 1980 was excluded regarding this date restriction as appropriate given changes 
in hypertension guidelines and clinical practice over the past  three decades. No 
language restrictions were applied. The most recent comprehensive search for each 
database was performed on 7 August, 2010. 
Additionally, we handsearched proceedings of the International Society of 
Hypertension, American Society of Hypertension & European Society of 
Hypertension in 2008 – 2010 for unpublished / ongoing studies.  We also searched 
the reference lists of included papers and former reviews on compliance issues in 
hypertension management to identify additional citations. We planned to contact 
some study authors if important questions arise and reserved an option to contact 
experts in the field about other relevant trials or unpublished material. 
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Study selection 
Two investigators (SG and IF) screened the retrieved records (a title and 
abstract) independently. Both reviewers were physicians by qualification, holding 
PhD degrees in cardiology (SG) and clinical pharmacology (IF); one was a qualified 
hypertension specialist (SG). Each reviewer indicated whether a citation is potentially 
relevant (i.e. appearing to meet the inclusion criteria), is clearly not relevant, or gives 
insufficient information to make a judgment. Printed copies of all potentially relevant 
citations were obtained.  
Both investigators assessed copies of all presumably relevant articles 
independently according to the above criteria. An option to appeal to a third reviewer 
was reserved in case of disagreement.  Every opinion differences were then resolved 
by discussion and consensus making. To be included in the review, a study had to 
meet our selection criteria and had not to meet any exclusion criterion. 
Data extraction 
The information was collected with use of a structured data extraction form 
(Appendix 3).  The form was developed with use of a prototype recommended by the 
Center for Reviews and Dissemination.[24]  It was pilot-tested on 4 randomly-selected 
included studies and refined. Data extraction was undertaken by the same two 
independent reviewers. The source and the authors of publications were not blinded. 
The data obtained in duplicate were then compared and discussed; consensus data 
were used in the review. 
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Quality assessment 
A special study quality evaluation form was developed to assess and present 
methodological quality characteristics of included studies in a descriptive format 
(Appendix 4) based on the Cochrane risk of bias tool,[25] thereby providing an 
accessible and objective summary. The same two reviewers provided data for the 
form independently and in duplicate, with further discussions and consensus making. 
Additionally, overall  judgment on study quality was made with use of a four-point 
continuum (“high”, “moderate”, “low” or “very low”)  according to the grading 
system developed by  CHERG Review Groups on Intervention Effects[26] (Appendix 
5). Typically, RCTs received an initial grade of “high”, observational studies (OS) 
received an initial grade of “low” (in case of large well-designed cohort studies – 
“moderate”). An initial score may be downgraded in case of important risk of biases, 
or, alternatively, a score may be upgraded one level if the researchers either 
controlled or accounted for all plausible confounders that would have modified the 
effect of the intervention on the health outcome. 
As significant heterogeneity in studies design, methods and outcomes 
measures was anticipated, no quantitative synthesis (meta-analysis) was planned. A 
narrative approach to data synthesis was adopted. A checklist of items to include 
when reporting a systematic review in accordance with the PRISMA guidelines[27] 
was filled and submitted along with the full text of the review (Appendix 6). 
  
Results 
Study selection   
The results of the review process with reasons for exclusion are displayed as a 
flow diagram (Figure 1, p.10). The original database searches and reference 
screenings identified 752 titles and abstracts; 688 were excluded after screening the 
abstract.  Full-text copies of 64 papers were obtained and assessed for eligibility. The 
most common reasons for exclusion were a study design not intended to compare 
groups with and without CGMM interventions (or their different components); a 
study design or report not included compliance measurement.  A total of 12 papers 
reporting 13 studies met the inclusion criteria.[28-39] One study had a complex 
structure with 2 phases of completely different design and in the review context they 
were considered separately.[34] 
Study characteristics 
Table I (pp. 13-17) illustrates an overview of study characteristics. The studies 
(5 observational ones, 2 cluster-RCTs, 6 - RCTs) incorporated a total population of 
approximately 2150 patients with hypertension,  with study arms ranging in size from 
18[35] to 219.[39] The trial populations were relatively small, six trials included less 
than 100 patients in all arms.[28,30-32,35,38] Twelve studies were single centered, and 
only one was multicentered.[33] Five studies were conducted in the United 
States;[28,29,34,37] all but one[28] were devoted to aspects of integrated care, including 
three related to complex team-based interventions involving pharmacists.[34,37] Of the 
non-USA trials, four were Swiss-based, generated by a single research center;[30-32,37] 
others were conducted in Spain,[33] Germany,[35] Netherlands[36] and Poland.[39] 
Wherever funding was reported, trials were frequently supported by  pharmaceutical 
companies[32,33, 35,38,39] or independent sources. 
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Figure 1 Flow diagram of study selection 
 
1095 records identified through 
databases searching 
134 additional records 
identified through other sources 
752 of records after duplicates removed 
752 of records screened 688 of records excluded 
64 full-text articles 
assessed for eligibility 
12 papers (13 studies) 
included in  
narrative data synthesis  
52 of full-text articles excluded 
due to the next main reasons: 
22  -  study design not intended 
to compare groups with and 
without CMGM (or its 
components); 
17  -  study design or report not 
included compliance 
measurement; 
7  -  protocols; 
3  -  not reported outcomes 
except compliance; 
2  - case studies; 
1  -  not designed to test 
pharmacological treatment 
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All studies included patients with mild-to-moderate hypertension, 
predominantly treated, but uncontrolled, with different degree of treatment regimen 
intensity. Only three studies included a portion of previously untreated patients.[33, 
37,39] The term for which patients had been diagnosed with hypertension was not 
stated in any study. Two trials included exclusively elderly patients with multiple 
chronic conditions and medications,[29,34] one of them included predominantly male 
veterans.[34]  Only four trials[29,32,34,37] reported patients’ ethnic origin, these were all 
predominantly white. Information about baseline level of patient compliance from 
different sources was available in four studies.[29,34,36,37] Six trials were performed in 
primary care settings,[28,29,33,36,38,39] seven - in specialized conditions of tertiary care 
(university clinics, hypertension units).[30-32,34,35,37] 
With regard to the use of antihypertensive medications according to treatment 
plans during a study period, approaches used were quite different in nature and 
activity. In the studies of McKenney et al[28] and Waeber et al[30] drug treatment 
regimens were stable throughout the study arms. In three trials medication changes by 
physicians were permitted, but not specified;[29,34] in a trial by Marquez Contreras et 
al[33] a pre-specified standardized algorithm of drug regimen change based on clinical 
guidelines was implemented in all patient groups.  In three trials pre-specified 
treatment strategy was based on the introduction in the treatment plan of a 
contemporary once daily medication (angiotensin II receptors antagonist) with option 
of addiction / changes of other medications according to a pre-specified algorithm[33] 
or at physician’s will.[35,39]  In a study by Wetzels et al [36] ECMD use for two months 
without medication changes was compared with UC care during which medication 
changes were permitted. In two observational before-and-after studies of similar 
designs by Bertholet et al[31] and Burnier et al[32] electronic monitoring was  
performed for one or two months without drug adjustments, and then elective 
monitoring (in case of previous non-optimal compliance) was combined with drug 
regimen adaptation if needed. Finally, in two studies of team-based care by Carter et 
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al[37] and Santschi et al[38] clinical pharmacists, according to trial designs, played a 
very active role to motivate treating physicians for treatment regimens optimization 
following current guidelines; and in the longest up to date RCT by Santschi et al[38] 
developed on the experience of previously mentioned observations,[31,32] during the 
first two months treatment changes were not permitted in all arms, followed by free 
drug changes in all arms on discretion of a general practitioner. 
 Seven trials  employed an ECMD as  compliance  management    
intervention;[28,30-32,35,36,38,39] in the rest of studies pill counts or patient self-reports 
were used as a CMGM component (addicted with some feedback in intervention 
group(IG)), and as a surrogate pre-specified outcome.[29,33,34,37] Regarding the nature 
of CMGM interventions, five studies tested solely compliance management as 
intervention, all exclusively with use of an ECMD.[30-32,36,39] The others were devoted 
to complex interventions including certain CMGM as a component, in companion 
with patient self-control activities,[28] education and/or motivational counselling,[29,33, 
35] under the frame of pharmaceutical care[34] or physician/pharmacist team-based 
care.[37,38] No placebo-compared (sham compliance management) studies were found. 
One study compared different CMGM approaches (compliance  monitoring with and 
without feedback);[35] in two studies UC addicted with compliance measurement (pre-
specified as an outcome) was used as a comparator;[37,39]  in one study of prolonged 
pharmaceutical care by Lee et al[34] a CG had recent long-term exposure to the same 
complex intervention with CMGM component. The frequency of compliance 
feedback to the patient across the trials ranged from once in 1 or 2 months[31,32] to 
everyday reminding in case of an interactive (with audio/visual reminder) ECMD 
use.[28,35,39] Two studies by Lee et al[34] and Wetzels et al[36] dealt with the problem of 
persistence of an effect of compliance intervention after its discontinuation. The 
majority of studies had at least 6-month follow-up, [28,29,33,34, 37-39] but only one with a 
small sample size reached the period of 12 months.[38] 
  
Table I Characteristics of included studies 
Reference 
(Study 
acronym)  
Design Dura-
tion 
Total N 
of pati-
ents (by 
arms) 
Hyper-
tensive 
popu-
lation 
Setting Components of 
CMGM 
as intervention 
C measures Compa-
rator(s) 
Pre-specified 
outcomes 
CMGM alone 
Bertholet  
et al [31] 
OS 
without 
control 
(before-
and-after) 
Up to 2 
months + 
up to 2 
months 
71 Treated 
(1-3 
drugs), 
uncont-
rolled 
Tertiary 
care, 
hyperten-
sion center 
Monitoring, every 
day for 1 or 2 
months + feedback 
to patient and 
physician at the end; 
then elective 
monitoring, every 
day 
ECMD for each 
drug, taking C* 
--- Office BP values, 
changes, control 
rate 
Burnier 
 et al [32] 
OS 
without 
control 
(before-
and-after) 
2 months 
+ 2 
months 
41  Resistant 
to triple 
therapy 
Tertiary 
care, 
hyperten-
sion center 
Monitoring, every 
day for 2 months + 
feedback to patient 
at 2 months; then 
elective monitoring, 
every day 
ECMD for each 
drug, taking C* 
--- Office BP values 
and changes, 
control rate+ 
ABPM values 
Christen-
sen et al 
[39] 
Cross-
over 
RCT 
6 months 
+ 6 
months 
219 /179 Untreated 
or ineffec-
tively 
treated  
Primary 
care 
IG: Monitoring, 
every day + feedback 
to patient 
(reminding), every 
day 
CG: None of above 
IG: ECMD for 
one  drug, taking 
C,  
dosing C**, 
timing C***,  
drug 
holidays****; 
IG, CG: patient 
self-reporting   
UC with C 
self-
reporting  
Office BP values 
and changes 
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Reference 
(Study 
acronym)  
Design Dura-
tion 
Total N 
of pati-
ents (by 
arms) 
Hyper-
tensive 
popu-
lation 
Setting Components of 
CMGM 
as intervention 
C measures Compa-
rator(s) 
Pre-specified 
outcomes 
Waeber  
et al [30] 
OS 
without 
control 
(before-
and-after) 
3 months  35  Treated, 
uncont-
rolled 
Tertiary 
care, 
hyperten-
sion center 
Monitoring, every 
day for 3 months + 
feedback to patient  
ECMD for one 
drug, taking C* 
--- Office BP values 
Wetzels  
et al [36] 
RCT 2 months 
+ 3 
months 
168/90 Treated, 
uncont-
rolled 
Primary 
care 
IG: Monitoring, 
every day for 2 
months + feedback 
to patient at 2 
months 
CG: None of above 
IG: ECMD for 
each drug, 
taking C* 
UC Office BP values, 
changes, control 
rate; drug 
regimen changes 
CMGM in complex interventions 
Friedman  
et al [29] 
RCT 6 months 133/134 Elderly, 
treated, 
uncont-
rolled 
Primary 
care 
IG: Self-report +  
feedback to 
physician, every 
week 
CG: None of above 
IG: Patient-self 
report to 
telephone-linked 
computer 
system;  
IG, CG: Pill 
count#  
UC  Office BP values, 
changes; 
Patient 
satisfaction; 
Incremental cost-
effectiveness 
Marquez 
Contreras  
et al [33] 
(ETECU
M-HTA) 
Multi-
center 
RCT 
6 months 184/172/ 
182 
Treated 
and un-
treated, 
including 
newly 
Primary 
care 
IG(Telephone) 
Self-report + feed-
back to patient,  
3 times over study 
IG(Mail), CG: 
IG (1): Patient-
self report 
during telephone 
interview;   
IGs, CG:  Pill 
UC Office BP values, 
changes 
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Reference 
(Study 
acronym)  
Design Dura-
tion 
Total N 
of pati-
ents (by 
arms) 
Hyper-
tensive 
popu-
lation 
Setting Components of 
CMGM 
as intervention 
C measures Compa-
rator(s) 
Pre-specified 
outcomes 
diagnosed none of above count# 
(only two drugs) 
McKen-
ney et al 
[28] 
 
RCT (2 
phases) 
12 weeks 
+ 12 
weeks 
70 Treated, 
uncont-
rolled, 
mostly 
elderly 
Primary 
care 
IG: monitoring, 
every day + 
feedback to patient 
(audiovisual 
reminding), every 
day  
IG: ECMD as 
timepiece cap on 
vials of each 
drug with 
reminding 
(alarm + flash); 
IG, C: pill 
count# 
UC (Phase 
I); UC, 
ECMD + 
diary 
(cards) of 
office BP; 
ECMD + 
home BP 
measure-
ment with 
cards 
(Phase II) 
Office BP values 
Mengden 
et al [35] 
OS with 
quasi-ran-
domized 
compo-
nent 
4 weeks 
run-in + 
8 weeks 
18/20/ 
24 
Treated, 
resistant  
on >2 
drugs 
Tertiary 
care 
Group A and B: 
Monitoring only, 
every day; 
Group C: Moni-
toring with feed-
back to patient 
(visual remin-
ding),every day  
All groups: 
ECMD, taking 
C*, dosing C** 
C moni-
toring  
without 
feedback 
Office and home 
BP values and 
changes + ABPM 
values, changes 
and control rates  
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Reference 
(Study 
acronym)  
Design Dura-
tion 
Total N 
of pati-
ents (by 
arms) 
Hyper-
tensive 
popu-
lation 
Setting Components of 
CMGM 
as intervention 
C measures Compa-
rator(s) 
Pre-specified 
outcomes 
CMGM in integrated care environment 
Carter  
et al [37] 
Cluster 
RCT 
9 months 101/78 Mostly 
treated 
Tertiary 
care 
IG: Measurement + 
feedback to clinical 
pharmacist at 
baseline, 2, 4, 6, 8, 
9 months  
CG: Measurement 
only at the same 
time 
IG, CG: Pill 
count## 
UC with 
increased 
surveil-
lance and 
informa-
tion sup-
port, C 
measure-
ment 
Office BP values, 
changes, control 
rate + ABPM 
values; 
drug regimen 
changes; 
adverse effect 
score 
Lee et al 
[34] 
(FAME, 
Phase I) 
OS 
without 
control 
(before-
and-
after) 
2 months 
run-in + 
6 months 
159 Elderly, 
mostly 
men, 
treated 
Tertiary  
care 
Measurement + 
feedback to patient 
by clinical 
pharmacist, every 2 
months 
Pill count# --- Office BP values, 
changes 
Lee et al 
[34] 
(FAME, 
Phase II) 
RCT 6 months  83/76 Elderly, 
mostly men, 
treated under 
pharma-
ceutical care 
Tertiary  
care 
IG: Measurement + 
feedback to patient 
by clinical 
pharmacist, every 2 
months 
CG: Measurement 
only at baseline 
and at the end 
IG, CG: Pill 
count# 
UC with 
previous 
recent 
pharma-
ceutical 
care 
Office BP values, 
changes 
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Reference 
(Study 
acronym)  
Design Dura-
tion 
Total N 
of pati-
ents (by 
arms) 
Hyper-
tensive 
popu-
lation 
Setting Components of 
CMGM 
as intervention 
C measures Compa-
rator(s) 
Pre-specified 
outcomes 
Santschi 
et al [38] 
Cluster 
RCT 
12 
months 
34/34 Treated, 
uncont-
rolled 
Primary 
integrated 
care 
(general 
practitioners 
and 
pharma-
cists) 
IG: Monitoring, 
every day (elective 
after 2 months) + 
feedback for 
patient and 
physician via 
pharmacists at 2, 4, 
6 and 12 months; 
CG: None of above 
IG: ECMD for 
one drug, taking 
C* 
UC Office BP values, 
changes; 
drug regimen 
changes 
 
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; C, compliance; CG, control group, CMGM, compliance 
measurement-guided management; ECMD, electronic compliance monitoring devices; IG, intervention group; OS, observational study; 
RCT, randomized controlled trial; UC, usual care. 
 
*Number of days (in percent), during which the prescribed number of doses were recorded as taken by electronic device.  
**(number of days with the correct number of device activations during a certain period  / number of days in the period)x100. 
***(number of correct dosing intervals during a certain period / number of dosing intervals during the period)x100; correct 
dosing intervals are prescribed dosing interval +25%. 
**** (number of calendar days without device activation during a certain period / number of calendar days in the same period) x100. 
#Percent of total number of tablets (capsules, patches) dispensed minus the total number counted in the audit divided by that should be 
taken by each subject during the period analyzed. 
##Percent of predicted doses measured at each visit. 
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Table II  Quality assessment of included studies 
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CMGM alone 
Bertholet  
et al [31] 
No NA No Yes §  NA NA NA NA ?** Yes Yes No Low 
Burnier 
 et al [32] 
No NA No Yes §  NA NA NA NA ?** Yes Yes No Low 
Christensen 
et al [39] 
Yes ? No Yes § a  Yes ? b No No ? No Yesc No Mode-
rate 
Waeber  
et al [30] 
No NA No Yes §  NA NA NA NA ?** Yes Yes No Low 
Wetzels  
et al [36] 
Yes Yes Yes d Yes § e §f  No Yes Yes Yes Yes Yes Yes Mode-
rate 
CMGM in complex interventions 
Friedman  
et al [29] 
Yes Yes Yes   Yes §k Yes ? ? Yes ? ** Yes No No Mode-
rate 
Marquez 
Contreras  
et al [33] 
(ETECUM-
Yes Yes ? Yes § Yes Noo No No Yes  Yes No No Mode-
rate 
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HTA) 
McKenney 
et al [28] 
? ? No Yes § No*** ? Yes No ? ** No Yes No Low 
Mengden  
et al [35] 
No No No §p § §q Nor No No ? ** Yes Yes No Low 
CMGM in integrated care environment 
Carter  
et al [37] 
 
Yes No Yes Yes § §g Noh Yesi Yes Yes j Yes Yes Yes          High 
Lee et al 
[34](FAME, 
Phase I) 
No NA No   Yes l § NA NA NA NA ? ** Yes Yes No Low 
Lee  
et al [34] 
(FAME, 
Phase II) 
Yes Yes No   Yesk § §m Nom Yesn Yes ? ** Yes Yes Yes High 
Santschi  
et al [38] 
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? , Cannot tell; §, partially; CMGM, compliance measurement-guided management; NA, not applicable. 
* Based on presented criteria. 
** Calculations not reported. 
***Groups were unbalanced on baseline DBP. 
a  Described only as untreated or ineffectively treated.  
b Based on telmisartan in all groups. 
c Potentially fraudulent data identified. 
d Measurements at baseline performed by physician, throughout  the study by research nurse. 
e Local definition of hypertension according to BP level. 
f Higher proportion of men in CG. 
g Higher baseline medication adherence score in CG; addressed in analysis. 
h Antihypertensive treatment regimens actively changed during study. 
i Number of visits differ between groups; addressed in analysis. 
j Did not reach the most conservative estimate. 
k More then 70% of sample suffered from isolated systolic hypertension .  
l Based on age and number of medications (4 or more); hypertensives presented more then 90% of sample. 
m More medications for psychiatric problems and angiotensin-converting enzyme inhibitors in IG; addressed in analysis. 
n According to study design, participants of IG (pharmaceutical care) received a regular follow-up, wile controls did not. 
o Candesartan-based treatment; addition of diuretic was lower in CMGM-group. 
p Exclusion criteria not specified. 
q Prevalence of diabetes mellitus differed between groups. 
r In 2 groups candesartan/hydrochlorothiazide was introduced. 
s Lower age, higher systolic and lower diastolic BP in CG; addressed in analysis.  
t Not calculated; based on authors’ assumption.  
 
  
The commonly used pre-specified outcome of the trials was the effect of the 
interventions on direct measures of office BP,  in  seven  ones  BP  control  rates  was 
also evaluated;[31-33,35-38] and three studies used repeated ambulatory blood pressure 
monitoring (ABPM) as the most objective measure of BP changes.[32,35,37] Three trials 
also pre-specified and assessed drug regimen changes as an outcome,[36-38] one 
reported changes in adverse effect score[37] and only one study by Freedman et al[29] 
partially addressed incremental cost-effectiveness of as well as patient satisfaction of 
the intervention using a telecommunication system. 
Study quality assessment 
Table II (pp. 18-20) presents the outcomes of the study quality assessment. 
Overall, the methodological quality of the included trials varied from low in case of 
OS[30-32,34,35] to high[34,37] with tendency to improvement of the quality of reporting 
over time. As a rule, quality criteria were not met due to lack of reporting, rather then 
due to specific reporting of inadequate methods. 
All RCTs stated that patients were randomly allocated to treatment groups and 
all but one[28] described the method of randomization; however, only four  trials[29, 
33,34,36] supplied sufficient details about sequence generation indicating allocation of 
participants was adequately concealed;  in other cases to make such a judgment  was 
not possible. With regard to blinding, it would be unreasonable to expect patients or 
personnel to keep blinding as to allocation in trials incorporating CMGM due to very 
different comparator groups. It should, however, be possible to blind assessors, but 
only three trials[29,36,37] provided positive information regarding the blinding of 
assessors.  No trial reported any assessment of blinding procedures.  
All trials reported patient eligibility criteria, and baseline comparability was 
achieved or partially achieved with exception of one study[28] where important 
differences in baseline DBP between study arms were not addressed in analysis.   
Overall, the studied disease description was not comprehensive, with provision of 
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some aspects that differed across studies. Details about hypertension diagnosis 
verification, in part, about identification and exclusion of cases with secondary 
hypertension, were not reported in any study. Studies performed at university clinics 
or hypertension centers recruited very selective samples of participants referred to 
tertiary care services with possible important peculiarities in nature of the disease and 
compliance issues.[30-32,34,35,37] 
Co-interventions in case of CMGM composed of complex experimental 
approaches were well reported. In some cases additional concerns about validity of 
results generated by confounding in organization of care were noted.  As it was 
indicated, in a study by Wetzels et al[36] medication changes in the CG were 
permitted for the first 2 months, although in the IG they were not; this could have a 
major impact on conclusions showing fewer drug changes under intervention 
(ECMD) for the whole study period of 5 months.  In other studies physicians could 
change some or all drug regimens at their free discretion throughout a study and its 
arms without appropriate documentation, making impossible to control such 
confounding.[31,32,35,39] In contrast, in two studies devoted to effectiveness of 
physicians / pharmacists collaboration active medication changes throughout the 
studies were recorded and reported as well as addressed in statistical analyses.[37, 38] 
The precision of evaluation of the most common outcome – office BP - was 
different due to fluctuations of measurement techniques and calculations of BP level 
data across studies. Measurements performed by the physician at baseline, and then 
throughout the study by a research nurse might introduce a “white coat” component 
in baseline BP levels and hence overestimate registered BP changes.[36] In one study 
by Christensen et al[39] employed everyday compliance monitoring via an ECMD a 
subjective method of compliance measurement (patient self-questionnaire filled once 
in 6 months) was used as a reference outcome measure which probably compromised 
data analyses and study conclusions.  
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Intention-to-treat (ITT) analyses were declared and performed in five 
studies.[34,36,37,38] All but three trials[29,33,38] reported numbers of attrition and 
exclusions with reasons. Only studies by McKenney et al[28] and Christensen et al[39] 
were included less then 80% of enrolled participants in the final analysis at least in 
some treatment arms. All reports were free of suggestion of selective outcome 
reporting.  
Effectiveness of interventions 
The preceding sections indicate that the included trials were of different 
quality and the interventions and comparators were heterogeneous. These factors 
argue against any statistical meta-analysis of the data; a narrative summary of results 
was therefore compiled. This section presents a narrative summary of intervention 
effects on the most common and clinically important outcome - BP - grouped by 
CMGM type (i.e. CMGM alone or in combination with another approaches to 
improve compliance and / or treatment outcomes; ECMD or other compliance 
measure) and by comparator: UC, UC with some advances, and different composition 
of CMGM components. Special attention in description of CMGM effectiveness was 
paid to nature and changes of antihypertensive medication during investigation 
according to a study design. Levels, changes of compliance and their relation to the 
outcome of interest were also addressed. Table III (pp. 30-36) summarizes these 
findings. 
CMGM alone  
In three OS[30-32] with obligatory ECMD use for 1-3 months significant 
improvement of BP levels and control rates were achieved in previously uncontrolled 
patients without any changes in medications. It was demonstrated under 
polypharmacy conditions[31,32] as well as under monotherapy.[30] These positive 
results were accompanied by extremely high compliance rate exceeding 90%.  
Continuation of elective compliance management in some patients and medication 
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adjustments in others under investigators’ discretion beyond 1-2 months provided 
additional benefit in one study.[31] This benefit was not confirmed by 4 months in 
another study with use of ABPM.[32]    
 Two RCTs compared CMGM with use of ECMDs with UC.[36,39] In the study 
of Wetzels et al[36] medication adjustment in CG of previously uncontrolled 
hypertensives  resulted in more favourable BP changes and control rate than in IG of 
CMGM without drug regimen optimization during the first 2 months, despite high 
compliance rate (more then 95%) in IG.  When CMGM was stopped and medication 
changes were permitted in both groups, BP differences between study arms were 
disappeared by 5 months.  The study sample was comprised of patients with high 
prevalence of persons with previous satisfactory adherence based on pharmacy refill 
rates.  
 In the RCT of Christensen et al[39] introduction of CMGM (ECMD with 
reminding) was compared in crossover fashion with UC against the background of 
treatment switch to telmisartan-based regimens. After the first six months, the groups 
of CMGM and UC were not different in BP changes with tendency to a higher rate of 
self-reported compliance in the IG.  After the next 6 months, no significant BP 
differences were occurred between the group of UC after initial CMGM and the 
group of postponed CMGM. The study participants consistently reported high levels 
of compliance that were not corroborated by electronic monitoring data of telmisartan 
use (52% after 6 months of ECMD use; 38% after 12 months including 6 months of 
postponed ECMD use). The study is characterized of extremely high dropouts and 
withdrawals rates; in part, certain electronic monitoring data were excluded from the 
analysis due to doubts about their authenticity. 
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CMGM as a component of complex interventions 
In four studies of original complex designs CMGM combined with some other 
activities to increase compliance was tested; in two of them ECMDs were implicated. 
In the two-phase RCT of McKenney et al[28] with older participants, the possibility of 
improvement of both BP level and compliance (based on pill counts) under CMGM 
(with use of reminding ECMD) compared with UC was initially demonstrated. Then 
the whole population was repeatedly randomized to groups under UC, with ECMD 
alone, ECMD along with structured diaries to be filled by patient and finally ECMD 
with home BP monitoring and diaries. Further decrease in SBP was documented 
following 12 weeks under all interventions without significant intergroup differences 
but not in controls (UC); the study arms were unbalanced in baseline DBP. The 
investigators aimed to conserve the treatment regimes throughout the study; in case of 
changes participants were excluded from the analysis. 
Mengden et al[35] studied several approaches in management of resistant 
hypertensives in one small short-term trial with a sophisticated design. After initial 
four weeks of ECMD use on standard drug regimens, participants with sufficient BP 
control as reflected by ABPM and BP self-monitoring (29%) were observed for the 
next eight weeks; in other patients a drug was replaced by fixed combination of 
candesartan and hydrochlorothiazide and they were divided into groups with ECMD 
with and without visual reminding function (everyday feedback to patient) along with 
continuing BP home self-measurement. The group equipped by reminding ECMD 
also received a structured hypertension teaching program. Compliance dynamics in 
initial four weeks were corresponded to BP control, with remarkable negative drive in 
uncontrolled participants. Changes in management resulted in stable compliance 
levels, improvement of BP and BP control rate (39%), without significant differences 
between groups with and without feedbacks to patients.   
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Friedman et al[29] tested a telephone linked computer system conversing 
weekly with elderly patients in their homes between office visits to their physicians. 
Computer-controlled speech included questions about compliance and gave feedback; 
patients communicated using the touch-tone keypad on their phones. Feedbacks on 
patent’s compliance was stored and forwarded as a printed report to his/her physician 
on a regular basis, and 40% of physicians discussed regularly the reports with their 
patients. Compared with UC, such type of CMGM resulted in marked positive 
changes in compliance indexes in spite of high pre-study levels estimated; however, 
they translated in significant DBP improvement only in previously non-adherent 
patients. 
In the multicenter RCT  of Marquez Contreras et al [33] telephone intervention 
(three telephone calls during the study made by expert nurses, which included patient 
compliance self-reports and their evaluation with motivation to desirable behaviour) 
was compared with mail intervention (three mailings with health and compliance 
education and reminding of the scheduled visits) and with UC. Standardized 
treatment step-care approach based on candesartan was implemented throughout the 
study. In result, compliance rate was higher in IGs compared with UC; the most 
pronounced positive BP changes was revealed in CMGM (telephone) group which 
were significantly different as compared with UC. 
CMGM in integrated care environment 
Four recent studies with the longest duration investigated different complex 
approaches reflecting and testing modern popular concepts of pharmaceutical care or 
team-based care as a tool to improve long-term management of chronic diseases.  
 In two phases of FAME study[34] the influence of pharmaceutical care on BP 
control was evaluated in elderly patients under multiple drug regimens for treatment 
of hypertension and concomitant cardiovascular disorders. Besides compliance 
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measurement and feedback, pharmaceutical care included simplification of 
medication delivery with use of customized blister packs and patient education 
efforts. In prospective 6-month observation (Phase I) patient compliance rate was 
markedly improved in pharmaceutical care group which resulted in SBP but not DBP 
reduction (By the way, BP values were not substantially increased at the Phase I 
entry). At entry to Phase II, patients were randomized to continued pharmaceutical 
care versus UC. Prolongation of the pharmaceutical care with CMGM component till 
the next 6 months maintained compliance rate at the same high level. It resulted in 
more pronounced SBP changes then in the CG which experienced the same 
intervention in previous 6 months. In this CG, compliance rate was significantly 
lower than in pharmaceutical care group, but significantly higher than the one at the 
Phase I entry. It is deserved attention that prolonged pharmaceutical care did not 
demonstrate additional benefit in Phase II for cholesterol reducing medications. 
 In the cluster RCT of Carter et al[37] the ability of a specific type of 
physician/pharmacist collaboration to improve BP control was studied. In the IG 
physicians and clinical pharmacists underwent team-building exercises; clinical 
pharmacists provided an educational patient interview at baseline and performed 
repeated meetings with a patient at pre-scheduled office visits and more often, if 
needed, in person or via telephone. Main contents of pharmacist/patient contacts were 
postulated as efforts to improve compliance based on its evaluation of a research 
nurse, and development of recommendations to the treating physician for drug 
regimens changes according to contemporary clinical guidelines, at the pharmacist’s 
discretion. Previous compliance rate in IG was significantly lower then in controls; it 
was improved during the intervention, so the differences disappeared. ABPM as well 
as office BP data were significantly better in IG which were reflected also by 
remarkably higher BP control rate. Clinical pharmacists were very active in making 
treatment recommendations to physicians, especially during the first 2 months of 
observation, and 96% of suggestions where accepted by physicians. In contrast, 
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specific recommendations on compliance were rarely developed by pharmacists. 
Significantly more frequent changes in medications regimens in IG resulted in 
significantly higher mean number of medications compared to controls, but without 
rise in adverse effect scores in both study arms. 
 The only one study of 12-month duration but small sample size[38] aimed to 
evaluate clinical efficacy of CMGM with ECMD as a component of integrated care 
with participation of pharmacists. After 2 months of obligatory use of ECMD in IG 
without drug regimen changes in both intervention and control arms, elective CMGM 
(depending on patient compliance data) as well as treatment changes were undertaken 
by treating physicians. Pharmacists were involved in ECMD handling, printing the 
adherence report during each patient visit, discussing the report with the patient and 
transmitting of it to the physician. Intervention group differed from controls in BP 
levels and control rates only after 4 months of the study; compliance rate in 
monitored patients was very high during the whole study term, and physicians tended 
to modify more frequently antihypertensive treatment in the IG.  
Non-hemodynamic outcomes of CMGM 
Three trials that pre-specified and assessed drug regimen changes as an 
outcome[36-38] reported conflicting results. Wetzels et al[36] revealed fewer drug 
changes and less drug use under CMGM, but these results may be related to baseline 
differences in antihypertensive drugs numbers between arms as well as to the study 
design not permitted drug changes in the first two months in the IG. In the Carter et 
al[37] were documented more intensive drug changes and more pronounced increase 
in mean drug numbers per day in IG, which may be attributed to active treatment 
regimen counselling generated by clinical pharmacists rather then CMGM per se. 
Finally, in the study of Santschi et al[38]  more frequent increase in numbers / dosage 
of antihypertensive medication in CMGM group were occurred which was not 
translated in sustained BP control improvement. 
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The only one study by Freedman et al[29] considered problems of patient 
satisfaction with a CMGM program with use of a questionnaire and a visual analog 
scale. 69% and 54% of patients scored overall satisfaction in the upper quartile of the 
corresponded tools. In the same study cost-effectiveness ratio of compliance 
management intervention was also tested. For DBP, the cost-effectiveness ratio for 
the whole studied group of hypertensives was 7,39 $ per 1 mm Hg decrease after 6 
months of CMGM. For non-adherent portion of patients, cost-effectiveness varied 
from 3,39 $ per 1 mm Hg improvement in DBP at 80% baseline adherence to 0,87 $ 
per 1 mm Hg improvement at 50% adherence. 
 
 
 
 
 
 
 
 
 
 
  
Table 3 Effectiveness of interventions 
  
 
Reference 
(Study 
acronym) 
 
Medication regimen 
 
 
Compliance 
 
Blood Pressure 
Previous 
drug 
numbers 
per day 
Nature of 
changes 
introduced 
Changes in 
drug 
numbers 
per day 
Previous 
level  
estimation 
Compliance data / 
dynamics 
 
BP levels / dynamics Dynamics of  
BP control rate 
Electronic compliance monitoring alone with feedback 
Bertholet  
et al [31] 
1 - 11%; 
2 - 22%; 
3 - 67% 
First 1 or 
2 months: 
no 
changes; 
next 1 or 2 
months: 
adjusted if 
needed, 
NSp 
NSp NSp After monitoring 
period of 1 or 2 
months: 
90,7% in subgroup 
with controlled BP; 
92,5% in subgroup 
with improved BP; 
91,6% in subgroup 
with uncontrolled BP 
SBP decreased from 
159±23 to 143±20* 
during monitoring and to 
133±20* mm Hg to the 
end of study; 
DBP decreased from 
104±12 to 92±15* and 
then to 
85±12*(mean±SD) 
After obligatory 
monitoring 
period: 
in 33,3% BP 
normalized 
(<140/90 mm 
Hg); in 33,3%  - 
BP improved 
(ΔSBP≥10; 
ΔDBP≥5 mm Hg) 
Burnier 
 et al [32] 
3; 
92% of 
drugs – 
once a day 
2 months: 
no 
changes; 
next 2 
months: 
adjusted if 
needed, 
NSp 
NSp NSp After 2 months:  
mean 93% (SD 9,3%) 
After 4 months: 
mean 94% (monitored 
patients) 
After 2 months: 
ΔSBP -11,5*; 
ΔDBP -9,1*; 
After 4 months: 
SBP, DBP, ABPM: no 
additional changes 
After 2 months: 
SBP from 0 to 
32% 
(40% based on 
ABPM); 
DBP from 0 to 
34% (25% based 
on ABPM) 
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Reference 
(Study 
acronym) 
 
Medication regimen 
 
 
Compliance 
 
Blood Pressure 
Previous 
drug 
numbers 
per day 
Nature of 
changes 
introduced 
Changes in 
drug 
numbers 
per day 
Previous 
level  
estimation 
Compliance data / 
dynamics 
 
BP levels / dynamics Dynamics of  
BP control rate 
Waeber  
et al [30] 
1 (mono-
therapy or  
fixed-dose 
combina-
tion) 
No 
changes 
No changes NSp 80,8±20,5% from 
167,9/100,4±16,3/7,2 to 
152,5/90,9± 20,9/11,5* 
(mean±SD) 
NSp 
Electronic compliance monitoring alone with feedback (reminding) vs. usual care 
Christen-
sen et al 
[39] 
1 - 5%;  
2-3 -
28%;  
4-5 -
30%; 
6-7 -
35%; 
>7 -2% 
Mean 4 
Telmisartan 
once a day; 
other  NSp 
NSp NSp Based on ECMD:         
In group using ECMD 
at entry: 51,8%;  
In group using post-
poned ECMD: 38,4%, 
Based on self-
reporting: 
early ECMD vs. UC: 
90,6% vs.85,1% (NS); 
UC after ECMD vs. 
postponed ECMD: 
88,4% vs. 86,3% (NS) 
After 6 months: 
early ECMD vs. UC: 
ΔSBP -28,8 vs. -28,3 
(NS); 
ΔDBP -13,4 vs. -13,6 
(NS); 
After next 6 months:       
UC after ECMD vs. 
postponed ECMD: 
ΔSBP -6,1 vs. -5,8 (NS); 
ΔDBP -3,3 vs. -3,2 (NS), 
NSp 
Wetzels  
et al [36] 
<2 - 46% 
(IG),74% 
(CG); 
2 months: 
no changes 
(IG), 
Net % of 
patients 
with dose 
% adherers 
(average 
refill 
After 2 months: 
95,3% (SD 10%), % 
of correct dosing 
After 2 months, IG vs. 
CG: 
ΔSBP -9 vs. -15*; 
After 2 months: 
38,6% (IG) vs. 
57,8% (CG)* 
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Reference 
(Study 
acronym) 
 
Medication regimen 
 
 
Compliance 
 
Blood Pressure 
Previous 
drug 
numbers 
per day 
Nature of 
changes 
introduced 
Changes in 
drug 
numbers 
per day 
Previous 
level  
estimation 
Compliance data / 
dynamics 
 
BP levels / dynamics Dynamics of  
BP control rate 
>2 - 54% 
(IG), 
26% 
(CG),  
 
adjusted if 
needed 
(CG); 
next 3 
months: 
adjusted if 
needed, 
NSp 
increase or 
drug 
addiction 
28,9 (IG), 
61,1 (CG) 
adherence 
>85%) 
based on 
pharmacy 
records 
81% (IG) 
vs. 77% 
(CG)  
>85% -95,8% (IG) ΔDBP -6 vs. -10*; 
After 5 months, IG vs. 
CG:  
ΔSBP -15  vs. -15 (NS); 
ΔDBP -10 vs. -10 (NS), 
After 5 months: 
53,7% (IG) vs. 
50,6% (CG) (NS) 
Electronic compliance monitoring and feedback (reminding) with and without patient structured diaries and home BP measurement      
vs. usual care 
McKenney 
et al [28] 
Mean 
1,6; 
1 - 46% 
No changes 
permitted 
No changes 
permitted 
NSp Phase I:  
IG: 95%; CG: 78%; 
Phase II:  
IGs: 
ECMD alone: 94%; 
ECMD + diary: 99%; 
ECMS + home BP + 
diary: >100%; 
UC: 79% 
After Phase I: significant 
decrease SBP and DBP 
in IG, but not in CG; 
After Phase II: further 
decrease in SBP in all 
IGs, with tendency to be 
more pronounced under 
combined interventions; 
in UC: tendency to 
increase BP 
 
NSp 
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Reference 
(Study 
acronym) 
 
Medication regimen 
 
 
Compliance 
 
Blood Pressure 
Previous 
drug 
numbers 
per day 
Nature of 
changes 
introduced 
Changes in 
drug 
numbers 
per day 
Previous 
level  
estimation 
Compliance data / 
dynamics 
 
BP levels / dynamics Dynamics of  
BP control rate 
Electronic compliance monitoring and feedback (reminding) with education vs. electronic compliance monitoring alone without feedback 
Mengden 
et al [35] 
>2 4 weeks 
run-in: no 
changes  
After 4 
weeks: Can-
desartan/hy-
drochloro-
thiazide 
once a day, 
replaced a 
drug 
(groups B 
and C) 
Increased 
from mean 
2,8 to 3,7 
(Group B), 
from 2,8 to 
3,6 (Group 
C) 
NSp After 4 weeks: 
In group A with 
sufficient BP control 
was stable; in others 
(group B+C) - 
decreased over time 
(*) and lower then in 
group A (*) 
After 12 weeks: 
In group A, group B 
(ECMD without 
feedback) and group C 
(ECMD with feedback 
+ education) was 
stable and comparable 
After 12 weeks, group C 
vs. group B, ABPM: 
ΔSBP -9 vs. -10 (NS); 
ΔDBP -4 vs. -6 (NS), 
 
After 4 weeks 
run-in, ABPM:  
29%; 
After 12 weeks, 
ABPM: 
Group B: 39%; 
Group C: 39%, 
Compliance measurement with telephone-based feedback and counselling vs. usual care 
Friedman  
et al [29] 
Mean 1,5 
(IG), 1,4 
(CG) 
NSp 
(changes 
permitted) 
No 
significant 
changes 
Mean 93% 
(IG), 94% 
(CG) by 
home pill 
Adjusted change IG 
vs. CG, total 
population: 
17,7% vs. 11,7%*; 
Adjusted IG vs. CG, total 
population: 
ΔSBP -11,5 vs. -6,8 
(NS); 
NSp 
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Reference 
(Study 
acronym) 
 
Medication regimen 
 
 
Compliance 
 
Blood Pressure 
Previous 
drug 
numbers 
per day 
Nature of 
changes 
introduced 
Changes in 
drug 
numbers 
per day 
Previous 
level  
estimation 
Compliance data / 
dynamics 
 
BP levels / dynamics Dynamics of  
BP control rate 
count) Adherent patients 
(took 80% or more 
drugs: 
0,6% vs. 3,0% (NS); 
Nonadherent patients: 
36,0 vs. 26,0* 
 
ΔDBP -5,2 vs. -6 (NS); 
Nonadherent patients: 
ΔSBP -12,8 vs. -0,9 
(NS); 
ΔDBP -6,0 vs. +2,8*, 
 
Marquez 
Contreras  
et al [33] 
(ETECUM
-HTA) 
NSp Standardized 
stepped algo-
rithm: from 
candesartan 
in the 
morning + 
hydrochloro-
thiazide + 
calcium 
antagonist or 
ACEI 
No 
significant 
differences 
between 
groups in 
numbers, 
but % of 
patients 
used 
diuretic was 
lower in 
telephone 
IG 
NSp Telephone IG vs. Mail 
(education) IG vs. 
CG: 
99,1% vs. 96,6% vs. 
89,6* (* by groups) 
Telephone IG vs. Mail 
IG vs. CG: 
ΔSBP -31,6 vs. -22,2 vs. 
22,1*(compared to 
Telephone IG); 
ΔDBP -19,7% vs. -12,9 
vs. -12,7* (compared to 
Telephone IG), 
 
Telephone IG: 
63,3%; 
Mail IG: 61,3%; 
CG: 
47,2%*(compared 
to Telephone IG), 
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Reference 
(Study 
acronym) 
 
Medication regimen 
 
 
Compliance 
 
Blood Pressure 
Previous 
drug 
numbers 
per day 
Nature of 
changes 
introduced 
Changes in 
drug 
numbers 
per day 
Previous 
level  
estimation 
Compliance data / 
dynamics 
 
BP levels / dynamics Dynamics of  
BP control rate 
Compliance measurement and feedback as component of pharmaceutical care 
Lee et al 
[34] 
(FAME, 
Phase I) 
Total 8,7  
(SD 3,1) 
Antihy-
perten-
sive  
2,52  
(SD 
1,15) 
No pre-
specified 
changes 
No signifi-
cant 
changes; 
antihyper-
tensive 2,55  
(SD 1,23) 
61,2% (SD 
13,5%) 
After 6 months of 
pharmacy care 96,9% 
(SD 5,2%), absolute 
change 35,5%* 
ΔSBP -3,3* 
ΔDBP -0,8 (NS) 
NSp 
Compliance measurement and feedback as component of pharmaceutical care vs. advanced usual care 
Lee  
et al [34] 
(FAME, 
Phase II) 
Antihy-
perten-
sive  
2,55  
(SD 
1,23) 
No pre-
specified 
changes 
No 
differences 
between 
groups 
IG vs. CG 
2,60 vs.2,61 
(NS) 
96,9% (SD 
5,2%) 
After 6 months  
IG (continued 
pharmacy care (12 
months in total)) 
95,5% (SD 7,7%) 
CG (stopped 
pharmacy care) 69,1% 
(SD 16,4%)* 
IG vs. CG 
ΔSBP -6,9 vs. -1,0*; 
Δ DBP -2,5 vs. -1,2 
(NS), 
NSp 
Compliance measurement and feedback as component of team-based care vs. advanced usual care 
Carter  
et al [37] 
IG: 1,5 
(SD 1,0) 
IG: Active 
changes 
IG: 2,4  
(SD 0,9) 
IG: 71,1% 
(SD 27,0%) 
IG: 94%  
CG: 92 % (NS) 
24 hour SBP before 
study, IG vs. CG: 135,5 
IG: from 0% to 
89,1%; 
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Reference 
(Study 
acronym) 
 
Medication regimen 
 
 
Compliance 
 
Blood Pressure 
Previous 
drug 
numbers 
per day 
Nature of 
changes 
introduced 
Changes in 
drug 
numbers 
per day 
Previous 
level  
estimation 
Compliance data / 
dynamics 
 
BP levels / dynamics Dynamics of  
BP control rate 
CG: 1,4 
(SD 1,0) 
according to 
guidelines 
suggested 
by clinical 
pharmacists 
CG: 1,9*  
(SD 1,0),  
more 
frequent 
changes in 
IG 
CG: 88,6 
%* 
(SD 20,9) 
 (SD11,3) vs. 136,0 (SD 
13,3) (NS); 
after study: 121,2 (9,9) 
vs. 131,3 (11,8)*; 
24 hour DBP before 
study, IG vs. CG: 76,0 
(9,8) vs. 76,6 (9,9) (NS); 
after study: 69,1 (8,6) vs. 
73,7 (8,0)* 
CG (with 
increased 
surveillance) : 
from 0% to 
52,9%, 
Electronic compliance monitoring and feedback as component of team-based care vs. usual care 
Santschi  
et al [38] 
47% - 1 
drug; 
IG: 2,5; 
CG: 2,2, 
First 2 
months: no 
changes;  
After: 
allowed, 
NSp 
IG: more 
frequent 
increase in 
numbers / 
dosage 
NSp IG: first 2 months 
96,9%; after 12 months 
97,1% (in selected 
patients) 
IG vs. CG: at 4 months 
143,4 (SEM 3,9) vs. 
154,3 (2,7)* mmHg; 
at other periods no 
significant differences, 
IG vs. CG, at 2 
months 24% vs. 
18% (NS); 
at 4 months 38% 
vs. 12%*; 
At 12 months 
21% vs. 9% (NS), 
*, significant differences; ABPM, ambulatory blood pressure monitoring; ACEI, angiotensin-converting enzyme inhibitor; BP, blood 
pressure; C, compliance; CG, control group, CMGM, compliance measurement-guided management; DBP, office diastolic blood 
pressure; ECMD, electronic compliance monitoring devices; IG, intervention group; NS, not significant; NSp, not specified; SBP, 
office systolic blood pressure; SD, standard deviation; SEM, standard error of mean; UC, usual care. 
  
Discussion 
The objective of this review was to assess the evidence of the effectiveness of 
CMGM procedures in treating adults with essential hypertension. We considered 
patient compliance monitoring, feedback and counselling as a health technology 
strategy designed to obtain timely information about level and dynamics of drug 
consumption with option to provide feedback to the patient (directly or via a health 
professional)  to correct his/her behaviour during hypertension management. To our 
best knowledge, we conducted the first systematic review of effectiveness of this 
novel approach, reflecting the new concept of CMGM as a sole intervention or a 
component of complex programs of integrated care in hypertension management.  
Characteristics of CMGM studies reviewed  
The systematic review included thirteen trials of different designs of 
approximately 2150 patients with no trials reporting data beyond 12 months even 
though hypertension management is a lifetime process. In five trials, CMGM 
programs with ECMDs were used exclusively as active interventions; no trials were 
identified which tested sole CMGM programs with use of other compliance 
measurement tools like self-reporting or pill counts. The rest of trials employed 
various CMGM programs as a part of complex interventions.  The studies differed 
also in nature of CMGM components, in part, in frequency and directions of feedback 
provided (to patients themselves, their physicians or other caregivers). Patients were 
described as having mild-to-moderate hypertension, predominantly treated 
unsuccessfully with different medication regimens.  The trials used BP levels and 
changes as the sole main clinical outcome.  This heterogeneity, combined with the 
insufficient quality of reporting, brought us to the conclusion that statistical analysis 
of the results would be inappropriate and, if presented, would be misleading. Instead, 
we assessed the level of evidence using trials’ main results, in relation to the content 
and comparators of CMGM, patients’ characteristics available, nature of 
antihypertensive drug treatment, compliance patterns and study quality. On the 
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whole, inconsistent trial results and the small numbers involved made generalization 
of results difficult. The authors of previous reviews devoted to ways of improvement 
of compliance and / or outcomes during hypertension management met similar 
problems in data handling and synthesis of findings. [15-20] 
CMGM alone  
It was essential to provide an initial estimate of the magnitude of the benefits 
and harms of CMGM as a discrete intervention before its consideration as a 
component of complex management programs. The revealed positive BP dynamics 
under CMGM with ECMDs in short-term (up to four months), mainly OSs  might be 
solely attributed to the non-specific so-called Hawthorne effect related to inclusion in 
trials.[40] This effect means subjects may improve their behaviour regarding 
medications being experimentally measured simply in response to the fact that they 
are being studied, not in response to any particular experimental manipulation.[41] 
Under the Hawthorne effect diminishing over time patients as well as their physicians 
respond differently when informed that BP control and/or medication taking would 
be carefully evaluated.  It may provide an explanation why in the reviewed trials BP 
improved over time even on constant medications regimens, and why in two RCTs of 
moderate quality sole ECMDs use failed to demonstrate additional benefit to BP 
values. All of these mean sufficient evidence is lacking that CMGM with modern 
ECMDs providing everyday automated monitoring of dosage execution improves BP 
control.   
CMGM as a component of complex interventions  
In  two trials of sophisticated design with  ECMDs use, augmented in some  
treatment arms by patient diaries, home BP monitoring or education, positive 
influence of the device use on BP was recorded. However, short duration and low 
quality of these trials did not permit us to attribute the results to real specific effects 
of CMGM and generated an unsolvable problem of differentiation of the effects of 
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the device alone, the device and feedbacks or additional components of intervention, 
and, finally, the Hawthorne effect just discussed.  
In two RCTs of moderate quality pill counts addicted by telephone-based 
compliance feedback between patients to a surrogate representative of their 
physicians were able to improve BP control compared with advanced UC or pure 
educational mail intervention.  Thus, some evidence exists that regular follow-up and 
supervising of hypertensive patients can be effectively implemented in the form of 
CMGM with use of telecommunication services. The key features of such services 
seem to be ability to provide easy and regular patient-physician interaction with 
necessity for a patient to report personally his (her) real activities.  
CMGM in integrated care environment  
In two US-based RCTs of the highest quality used a CMGM component 
incorporated in sophisticated integrated care with an active role of pharmacists  
statistically and clinically significant improvement of BP levels was reached. 
Surprisingly, the only one European RCT incorporating an ECMD in the CMGM 
process with participation of clinical pharmacists failed to demonstrate similar result. 
It might occur at least partly due to inherent problems in the study design based on 
the assumption of priority of compliance improvement over pharmacological 
regimens optimization.  
In any case, transferability of the kinds of pharmaceutical care or integrated 
care tested to other clinical practices outside and even inside the country of origin is 
very questionable, as it assumes availability and acceptance of qualified clinical 
pharmacists in the health care sector. To separate the impact of CMGM from other 
services (customized blister packs or active suggestions to physicians for treatment 
regimens optimization) in these results is not possible. Moreover, selected 
implementation of any components based on the trial results would be 
methodologically wrong, as it is completely unknown which components were 
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essential and which ones were ancillary. In these trials such complex interventions, 
while effective, represent undesirable silos and seem to be neither cost effective nor 
practical in implementation for highly prevalent chronic conditions such as 
hypertension. Integrated care is a novel concept which should be tested further 
according to general principles of the health technology assessment.[18] If we consider 
patient compliance (adherence) as a complex result of interactions between the 
patient, the physician and the health care system,[13] multifaceted plans for 
hypertension control deserve consideration. However, the effective components of 
such plans and their priorities must be identified in a systematic fashion. 
CMGM in hierarchy of interventions for hypertension management 
improvement 
Our review provided more insight in establishing priorities of interventions 
for stepped care approaches of hypertension management which claimed in previous 
reviews.[16,17]  Trials included in this review and dealing with electronic compliance 
monitoring were predominantly designed on the basis of hypothesis that lack of 
patient compliance is wide-spread, easily measurable and correctable with ECMDs; 
hence the last may be the first priority in attempts to improve BP control in 
previously unsuccessfully treated subjects; and after that drug administration 
regimens changes should  be considered[32,42]. Empirical evidence for this 
management algorithm has not been obtained. Instead, there was no advantage of 
ECMDs introduced according to the paradigm mentioned above versus approaches 
based on initial medication scheme optimization, provided it is made according to the 
modern evidence-based guidelines and especially along with introduction of modern 
drugs combinations based on the renin-angiotensin system antagonists with 
prolonged 24 hour action.  Such medications, frequently called as «forgiving drugs» 
for their ability to preserve BP control in case of an occasionally missed dose[43], 
represent simple, applicable and effective approach to improve BP levels and control 
rates, which makes electronic compliance monitoring (including the feedback to 
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patients via audiovisual reminding) unavailing, at least in some populations. 
Moreover, attempts to increase compliance with non-optimal treatment regimens with 
an ECMD in the RCT by Wetzels et al[36] was successful, but naturally resulted in not 
superior BP levels and control rates compared with UC. There are also theoretical 
grounds against «initial efforts for compliance changes» concept. First, problems in 
prescribing among physicians are not less common then problems in compliance 
among patients; it is especially true for drug treatment in hypertension often suffering 
form therapeutic inertia, requiring rational drug combinations and dosage 
adjustments[8]. Second, non-adherence to medication regimens in subjects regularly 
applying for medical services and all the more so participating in trials with 
compliance control may be not so pronounced as one in general population of 
hypertensives[19]. 
Indeed, in general, in the trials reviewed the level of patient compliance was 
quite high and stable, but in favour of IGs. It is not always translated into 
hemodynamic benefits, as noted also by others.[15,16]  It should be pointed out that the 
rate of compliance per se is neither an aim of management nor a surrogate guarantee 
of better treatment results[16]. Its precise relationships with different outcomes of 
disease management (including hard clinical endpoints, important surrogate 
measures, organizational outcomes, costs, etc.) should still be evaluated 
comprehensively.  That is why we are not concentrated in the review on compliance 
numbers as outcomes.  
The role of different CMGM components 
We did not find any definite evidence that CMGM with ECMDs use is 
superior in influence on any hypertension management outcomes compared with 
other compliance measures. In contrast, the patterns of feedbacks provided during 
CMGM programs seem to be of greater importance for treatment results. In trials 
with ECMDs use alone transmission of compliance data for treating physicians and 
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their discussions with patients were quite rare; these circumstances might affect the 
study results. The option of reminding to patients themselves incorporated in some 
modern ECMDs seems to have no sound effect. The central figure in the feedback 
processes should be the treating physician; however, it was revealed that different 
mediators (a nurse, an automatic call machine) recognized by the patient as the 
ambassador of his (her) doctor can reasonably increase the frequency of contacts and 
hence may be used effectively. These conclusions based on the available empirical 
evidence strictly correspond to the modern paradigm of patient compliance 
(adherence), assuming regular interaction of patient and physician on the matter in 
the process of treatment, in concordance with their initial agreement[13]. 
The role of populations  
Other predictors of trial results may be related to populations studied. CMGM 
is a complex behavioural process and patient characteristics also need to be 
considered. The studies were concentrated on a quite narrow pool of mild-to-
moderate hypertensive patients making generalization of conclusions to important 
groups of patients like ones with severe or complicated hypertension impossible. 
Higher BP levels at study entry could result in greater treatment effects than lower 
values, which may be subject to the so-called «floor effect» whereby only small 
further reductions are possible. Similar logics may be applied for compliance initial 
levels and changes, when we may anticipate more pronounced BP changes in case 
lower initial levels of compliance forwarding its marked improvement during 
CMGM. 
Non-hemodynamic outcomes of CMGM  
 The quantity and quality of the information regarding the influence of CMGM 
on outcomes other then hemodynamic ones are scarce. Up to date there is modest 
evidence that complex interventions incorporating CMGM component  might be 
accompanied by increase in drug regimen changes in certain cases, but this 
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relationship seems to be not casual. We can suppose that telecommunication-based 
CMGM with pill counts use is acceptable for patients and cost-effective, but it 
requires further evaluation.  
Almost nothing is known about patient satisfaction with ECMDs, but high 
dropouts of patients in some trials can indirectly indicate the problems of such kind.  
Another concern is feasibility of ECMDs in routine clinical practice, hence frequent 
attempts in designs of the evaluated studies to perform short-term and/or selective 
electronic compliance monitoring could mask the real effectiveness of the 
intervention. 
Limitations of the study  
A major concern to our review was the insufficient quality of existing trials. 
Any proposed future trials need to address the major design weaknesses highlighted 
in this review. The most important requirements to be fulfilled in future trials are 
need to be suitably powered to detect meaningful (clinically significant not just 
statistically significant) differences between arms, robust randomization, confounding 
addressed, ensuring adequate allocation concealment and blinding procedures when 
possible. Patient attrition must be not only adequately reported, but dealt with in any 
final intention-to-treat analyses.  
Other limitations of our study are generated from the limited scope of trials 
included. To create a comprehensive health technology assessment of CMGM not 
only BP changes must be considered, but also other clinically important hard 
endpoints and surrogate outcomes like end-organ damages, patients’ health-related 
quality of life and preferences, as well as economic and organizational outcomes. It 
should be pointed out that clinical, economic and patient-centered outcomes may be 
influenced in different directions.[44] Unfortunately, up to date patient-related 
outcomes and economic ones  are practically of scope of available studies of CMGM 
in hypertension. 
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 Opportunities for generalization of the results of the systematic review for 
different health care systems and settings are not yet available. It is known that 
behavioural patterns in physician-patient interrelationships are diverse in different 
socio-cultural contexts.  For example, patients in Eastern European countries usually 
tend to highly paternalistic relations with physicians on medication issues, whereas 
Western Europeans typically welcome cooperation.[45,46] Hence, they may 
substantially differ in their attitudes to various CMGM approaches.  
Finally, as only published studies were retrieved for this review, the finding 
may potentially overestimate the benefits of CMGM. 
Implications for future CMGM research 
The previous comprehensive reviews on patient compliance matters have 
applied quite strict criteria of study selection and based mainly or exclusively on 
RCTs.[15-17] Taking into account the results of the previous works as well as the new 
scope of the problem, we intentionally expanded the inclusion criteria to explore grey 
areas of research, to draw directions and to make suggestions for designs of future 
investigations.  We were convinced that CMGM research is ongoing and promising. 
However, they should be not only intensified, but, first of all, undergo prompt 
methodological changes.  
First, future studies should be thoroughly controlled for ongoing 
antihypertensive treatment confounding and incorporate currently agreed standards 
for pharmacological treatment of patients with hypertension. Further research could 
only be approved if CMGM is used in concordance with up-to-date high quality 
clinical guidelines for hypertension management. This argument also predetermined 
the scope and the time horizon of the current review.  
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Second, RCTs of high methodological standards with comparison of different 
complex approaches (preferably composed of two or three distinguishable 
components) for hypertension management improvement are of the highest priority. 
 Third, efforts for study planning and performing with evaluation of CMGM 
programs should be based on both ECMDs and other compliance measures (pill 
counts, pharmacy refill records, etc.) as each method of measuring compliance has its 
own strengths and limitations. Such studies should be concentrated on critical patient 
groups: elderly, subjects with multiple chronic disorders and/or with multiple drug 
regimens, with complicated and/or severe hypertension, other persons with pre-
revealed problems regarding compliance with medications.  
Forth, further research should be concentrated on effectiveness of 
comprehensive CMGM approaches incorporating all pre-specified components: 
compliance monitoring per se as a basic component, different models of feedback to 
the treating physicians, and counselling, with special attention to their frequency and 
possible combination with interactive psychological and behavioural procedures.  
Fifth, the evolution of the techniques of CMGM with ECMDs use should be 
addressed, as well as general progress in telemedicine, permitting novel opportunities 
for feedback via more sophisticated computer feedback equipment with use of 
personal smartphones and mobile computers.  
Hypertension is a lifetime disease and requires long-term pharmacological 
interventions which predetermine implementation of reliable and permanent 
supporting measures. Though there is a little wisdom to anticipate that the 
infrastructure of such measures must be rigid for years, trials of longer duration need 
to demonstrate true effectiveness of CMGM.  Such trials would need to address the 
existence and importance of the Hawthorne effect and the «white coat» effect; to 
avoid the last one the use of ABPM and/or home BP self-monitoring would be 
welcomed. Meantime, the useful information might be generated also from creation, 
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support and analysis of large, well-designed databases (registries) of hypertension 
management in different health care settings.  
  
Conclusions 
In this review devoted solely and comprehensively to immediate compliance 
management as a health technology, but not as a surrogate measurement tool, no 
sound evidence was revealed that CMGM with ECMDs use as a sole intervention has 
a specific influence on BP control in hypertension treatment. Limited short-term 
positive effects on BP and no long-term benefits of CMGM as a component of 
complex interventions were demonstrated. No studies were performed on influence of 
CMGM on mortality, morbidity, hypertension target organ damages as well as 
patient-reported outcomes and organization of care (with exception of drug regimens 
changes).  
Regarding the importance of different components of CMGM, regular 
feedback to the treating physician, but not to the patent himself seems to be essential. 
It may be realized via telecommunication and with participation of the physician’s 
“ambassador” (a nurse, a pharmacist). Such intermediate caregivers can increase the 
frequency of necessary feedbacks and intensify simultaneously the counselling 
component of CMGM.  
Pharmacological regimens optimization according to contemporary well-
prepared clinical guidelines, alongside with other quality improvement interventions, 
should precede any efforts on patient compliance management. Introduction of 
modern once daily preparations in the drug treatment plan may abolish the necessity 
of implementation of CMGM programs in mild-to-moderate hypertension.  
Although there may be other reasons to the use of this technology, we found 
no convincing evidence for the effectiveness of any particular CMGM approaches to 
make sound recommendations for their incorporation in hypertension management. 
This does not, however, mean the evidence of absence of CMGM effectiveness in 
view of non-optimal study designs and their methodological quality.  Any future 
research needs to be conducted using accepted quality standards and given 
contemporary guidelines for the treatment of hypertension, especially in relation of 
medication choice and prescribing.  Such studies should be concentrated on specific 
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groups of patients with compliance problems. To be considered as a useful and 
applicable health technology in the modern armamentarium of hypertension 
management in a particular healthcare setting not only hemodynamics but other 
outcomes of CMGM should be considered and tested in appropriate context  
including economic, patient-reported (quality of life, preferences and satisfaction) 
and organizational ones.  
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Appendices 
APPENDIX 1.  PICOS paradigm of the systematic review 
Population adult patients with verified essential hypertension 
Intervention patient compliance management (measurement, 
feedback, counselling) i.e. compliance measurement-
guided medication management (CMGM) 
Comparators comparison with no compliance management 
intervention  (“usual care”);  or comparison of 
different techniques of compliance measurement / 
management among themselves (different CMGM 
components) 
Outcomes any, including  
- clinical (blood pressure, morbidity, mortality) 
- organizational  (managerial) 
- patient-reported (humanistic) 
- economic 
Study design randomized controlled trials (RCT) 
(patient-randomized, cluster-randomized,   
quasi-randomized trials);  
cohort studies with or without controls (matched, 
unmatched, historic or internal) 
 
 
 
 
 
 
 
 
 
 
ii
 
APPENDIX 2.  MEDLINE search strategy 
Database: Ovid MEDLINE(R) <1950 to July Week 3 2010> 
1     exp hypertension/ (184961) 
2     blood pressure.ti. (37406) 
3     hypertens$.ti. (132155) 
4     or/1-3 (230673) 
5     exp patient compliance/ (40602) 
6     (patient$ adj7 (complian$ or non?complian$)).tw. (16304) 
7     (patient$ adj7 (adher$ or non?adher$)).tw. (8443) 
8     (patient$ adj7 (persistan$ or non?persistan$)).tw. (78) 
9     or/5-8 (56013) 
10     exp questionnaires/ (219586) 
11     (patient$ adj7 interview$).tw. (19447) 
12     Morisky.tw. (95) 
13     self-report$.tw. (52545) 
14     pill count$.tw. (407) 
15     ((pharmacy adj7 refill$) or (pharmacy adj7 claim$)).tw. (795) 
16     (biological marker$ or biomarker$).tw. (41232) 
17     (electronic adj3 device$).tw. (1979) 
18     (electronic adj3 monitor$).tw. (1480) 
19     medication$ event$ monitor$ system$.tw. (171) 
20     intelligent drug$ administration$ system$.tw. (1) 
21     or/10-20 (316290) 
22     exp counseling/ (27539) 
23     exp feedback/ (34150) 
24     exp patient care team/ (45628) 
25     counsel$.tw. (51070) 
26     feedback$.tw. (56041) 
 
 
 
iii
27     ((nurse$ or pharmac$) adj3 (led$ or manage$ or program$ or based)).tw. 
(21901) 
28     exp reminder systems/ (1545) 
29     remind$.tw. (7935) 
30     or/22-29 (210983) 
31     clinical trial.pt. (463526) 
32     randomi#ed controlled trial.pt. (295296) 
33     epidemiologic studies/ (4814) 
34     evaluation studies/ (137461) 
35     comparative study/ (1493859) 
36     feasibility studies/ (29901) 
37     intervention studies/ (4493) 
38     program evaluation/ (35669) 
39     epidemiologic research design/ (1378) 
40     (randomi#ed or controlled or intervention$ or evaluation$ or impact$ or 
effectiveness or stud$ or comparative or feasibility or program$ or design$).ti. 
(1738420) 
41     or/31-40 (3358091) 
42     animal/ not human/ (3427443) 
43     41 not 42 (2740402) 
44     (editorial or comment or letter).pt. (1013225) 
45     21 or 30 (512454) 
46     9 and 45 (11084) 
47     4 and 46 (609) 
48     47 and 43 (320) 
49     48 not 44 (319) 
50     limit 49 to yr="1980 -Current" (311) 
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APPENDIX  3. Data extraction form 
GENERAL INFORMATION 
Date of data extraction 
Reviewer ID 
 
 
Study ID  
Author(s) 
 
Article title 
 
Publication source: journal / year / volume / pages  
 
Country (geographical area) of origin 
Institutional affiliation(s) 
 
Contact address 
 
Sponsorships / conflict of interests 
 
SPECIFIC INFORMATION 
Verification 
of study 
eligibility 
Correct population Yes/No 
Correct intervention(s) Yes/No 
Correct outcome(s) Yes/No 
Study design  RCT / manner of randomization 
Cohort study with matched concurrent controls 
Cohort study with unmatched concurrent controls 
Cohort study with historic controls 
Cohort study with internal controls (before-after 
study) 
 
 
 
v
Other 
Population 
Inclusion criteria 
 
 
 
Exclusion criteria 
 
 
 
Recruitment procedures used/ participation rates 
 
 
Allocation concealment Yes/No/Unclear 
 
Characteristics of 
participants at 
intervention 
commencement 
 
Intervention group(s) 
 
Control group(s) 
Age   
Gender   
Ethnicity   
Education   
Habituation    
Socioeconomic 
status/occupation 
  
Other available 
details 
  
Number   
 
 
 
vi
Were intervention and control groups comparable? Yes/No/Partially - specify 
Disease 
Duration of hypertension 
Severity – mild / moderate / severe  
Previously treated Yes/No 
 
If treated: 
Controlled / uncontrolled (resistant) 
Previous treatment regimens details (if available) 
 
 
Previous compliance estimation (if available) 
 
Description of health care setting 
Primary / secondary / tertiary care / specialized hypertension units (centers) 
 
Qualifications of physicians (if available) 
 
Qualifications of allied caregivers (nurses, pharmacists, etc. – if appropriate) 
 
Intervention 
Important details of intervention(s) design and comparator(s) 
 
 
  
Nature / 
focus of  
CMGM 
intervention 
Solely compliance 
management 
Compliance measurement / evaluation  only 
 
Compliance measurement / evaluation and 
feedback to patients 
Compliance measurement / evaluation and 
feedback to caregivers (specify) 
 
 
 
vii
Compliance 
management as a 
component of 
complex 
interventions 
Compliance measurement / evaluation only 
 
Compliance measurement / evaluation and 
feedback to patients 
Compliance measurement / evaluation and 
feedback to caregivers (specify) 
Other components of complex interventions 
 
Compliance  
measures 
direct / indirect 
specify in each study group 
 
 
manner of expression / units 
 
provider 
Duration 
Frequency and total number of compliance checkpoints (including feedbacks if 
appropriate) 
Antihypertensive study medications 
Medication regimens changed during study – Yes (specify)/No 
Intervention group(s) Control group(s) 
  
 
 
Other co-interventions / differences in health care delivering 
Intervention group(s) Control group(s) 
  
 
 
 
 
 
viii
Outcomes 
Nature  
of pre-
specified 
outcome(s) 
  
Office BP values /  BP control rates  
Ambulatory (24 hours) BP values /  BP control rates 
Mortality  
Morbidity (specify) 
Adverse reactions 
Patient-reported (specify)  
Organizational (specify) 
Economic (specify) 
Assessor(s): Physician / Nurse / Pharmacist / Other 
Blinding of assessor(s): Yes/No/Unclear 
Details of BP measurements 
 
Analysis 
Sample size: calculated / actual, in each arm 
 
Follow-up: withdrawals rate, reasons (if specified), in each arm 
 
Intention-to-treat analysis: Yes/No/Unclear 
Statistical techniques used 
 
Adjustment for confounding 
 
Primary results 
Pre-specified 
outcomes 
Intervention group Control group 
Before After Before After 
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Statistical significance 
Other results 
 
 
 
Notes 
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APPENDIX  4 . Study quality evaluation form 
GENERAL INFORMATION 
Date of study evaluation 
Reviewer ID 
 
 
Study ID  
Author(s) 
 
Article title 
 
Publication source: journal / year / volume / pages  
 
Quality criteria Comments 
RCT: 
randomization 
procedure 
Yes / No / Cannot tell 
If yes: truly randomized /  quasi-randomized  
RCT: Allocation 
concealment 
Yes / No / Cannot tell 
Observational 
study: controls 
Matched / Unmatched / Historic / Internal 
Blinding Masking of outcome assessment: Yes / No / Cannot tell 
Comments 
 
Eligibility criteria 
specified 
Yes / No / Partially (specify) 
 
 
Population 
description 
Full / Incomplete (specify) 
 
 
Disease 
description 
Full / Incomplete (specify) 
Diagnosis verification Yes / No / Cannot tell 
 
 
 
xi
Health care 
setting description 
Full / Incomplete (specify) 
Study group(s) 
systematic 
difference  
In baseline characteristics of patient groups:  
Yes (specify) / No 
 
 
In organization of health care:  
access to physician’s visits, consultations, examinations, and 
other important features 
 
Intervention(s) 
description 
Full / Incomplete (specify) 
 
 
Medication 
regimen 
description  
Full / Incomplete (specify) 
 
Differences in medication strategies and regimens by groups 
Study duration   
 
Sample size Calculated: Yes / No 
Achieved: Yes / No  
Losses to follow-
up 
More then 80% in final analysis: Yes / No / Unclear  
 
Absolute numbers and proportions  
Intention-to-treat 
analysis 
Yes / No / Cannot tell 
 
Outcomes 
description 
Full / Incomplete (specify) 
 
Selective reporting  note 
 
 
 
 
xii
Statistical 
analysis 
Adequate: Yes / No 
 
If no, specify critique  
 
Control for confounding:  Yes / No 
Estimation for 
risk of biases   
selection bias: Yes / No 
comments 
 
performance bias: Yes / No 
comments 
 
measurement (observer) bias: Yes / No 
comments 
 
attrition bias: Yes / No 
comments 
 
Other 
notes 
 
 
 
 
 
 
Overall judgment on study quality  
 
High, moderate, low, very low 
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APPENDIX 5. Grading system for overall score of methodological quality 
(Adapted from [26]) 
1. Scoring system 
Each study is assigned a single score based on a four-point continuum: 
“high”, “moderate”, “low”, “very low”. 
2. Score for study design 
RCTs receive an initial grade of “high”, OSs studies receive an initial 
grade of “low” (in case of large well-designed cohort studies – 
“moderate”). 
3. Score adjustment 
After a careful assessment of study methods and execution based on 
information summarized in the study quality evaluation form, a score 
should be downgraded one level if there are serious questions about 
validity of results related to  
- sequence generation, allocation concealment, blinding (in case of  
RCT); 
- incomplete outcome data or selective outcome reporting; 
- other important sources / suspicion of  bias:  performance bias / 
Hawthorne effect; attrition bias / loss to follow-up; 
- sample size; 
- inconsistencies with other data sources. 
A score should be upgraded one level if the researchers either controlled 
or accounted for all plausible confounders that would have modified the 
effect of the intervention on the health outcome. 
Thus, a high quality study should be of high design (truly randomized RCT 
with successful allocation concealment and sufficient pre-calculated sample size or 
large cohort study with parallel matched controls) with blinding of assessors, follow-
up more then 80% of participants, adjusted for confounders and comprehensive 
description of participants, interventions and outcomes.  
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APPENDIX 6. Checklist of items to include when reporting a systematic review 
(According to the PRISMA Statement [27]) 
 
Section/topic 
 
# 
 
Checklist item 
Reported on 
page # 
TITLE 
Title 1 Identify the report as a systematic 
review, meta-analysis, or both. 
Title page 
ABSTRACT 
Structured summary 2 Provide a structured summary 
including, as applicable: background; 
objectives; data sources; study 
eligibility criteria, participants, and 
interventions; study appraisal and 
synthesis methods; results; 
limitations; conclusions and 
implications of key findings; 
systematic review registration number. 
i-iv 
INTRODUCTION 
Rationale 3 Describe the rationale for the review 
in the context of what is already 
known.  
1 
Objectives 4 Provide an explicit statement of 
questions being addressed with 
reference to participants, 
interventions, comparisons, outcomes, 
and study design (PICOS).  
4-6,  
Appendix 1 
 
 
 
xv
 
Section/topic 
 
# 
 
Checklist item 
Reported on 
page # 
METHODS 
Protocol and 
registration 
5 Indicate if a review protocol exists, if 
and where it can be accessed (e.g., 
Web address), and, if available, 
provide registration information 
including registration number.  
xii 
Eligibility criteria 6 Specify study characteristics (e.g., 
PICOS, length of follow-up) and 
report characteristics (e.g., years 
considered, language, publication 
status) used as criteria for eligibility, 
giving rationale. 
4-6, 
Appendix 1 
Information sources  7 Describe all information sources (e.g., 
databases with dates of coverage, 
contact with study authors to identify 
additional studies) in the search and 
date last searched.  
6 
Search 8 Present full electronic search strategy 
for at least one database, including 
any limits used, such that it could be 
repeated. 
Appendix 2 
Study selection  9 State the process for selecting studies 
(i.e., screening, eligibility, included in 
systematic review, and, if applicable, 
included in the meta-analysis).  
7 
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Section/topic 
 
# 
 
Checklist item 
Reported on 
page # 
Data collection 
process 
10 Describe method of data extraction 
from reports (e.g., piloted forms, 
independently, in duplicate) and any 
processes for obtaining and 
confirming data from investigators. 
7 
Data items  11 List and define all variables for which 
data were sought (e.g., PICOS, 
funding sources) and any assumptions 
and simplifications made. 
Appendix 3 
Risk of bias in 
individual studies 
12 Describe methods used for assessing 
risk of bias of individual studies 
(including specification of whether 
this was done at the study or outcome 
level), and how this information is to 
be used in any data synthesis. 
7-8, 
Appendix 
4,5 
Summary measures 13 State the principal summary measures 
(e.g., risk ratio, difference in means).  
8 
Synthesis of results 14 Describe the methods of handling data 
and combining results of studies, if 
done, including measures of 
consistency (e.g., I2) for each meta-
analysis. 
8 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias 
that may affect the cumulative 
evidence (e.g., publication bias, 
7-8, 
Appendix 
4,5 
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Section/topic 
 
# 
 
Checklist item 
Reported on 
page # 
selective reporting within studies).   
Additional analyses 16 Describe methods of additional 
analyses (e.g., sensitivity or subgroup 
analyses, meta-regression), if done, 
indicating which were pre-specified. 
Not done 
RESULTS 
Study selection 17 Give numbers of studies screened, 
assessed for eligibility, and included 
in the review, with reasons for 
exclusions at each stage, ideally with a 
flow diagram. 
9-10,  
Figure 1 
Study characteristics 18 For each study, present characteristics 
for which data were extracted (e.g., 
study size, PICOS, follow-up period) 
and provide the citations. 
9-12, 21, 
Table I  
(13-17) 
Risk of bias within 
studies 
19 Present data on risk of bias of each 
study and, if available, any outcome-
level assessment (see Item 12). 
21-23, 
Table II 
(18-20) 
Results of individual 
studies 
20 For all outcomes considered (benefits 
or harms), present, for each study: (a) 
simple summary data for each 
intervention group and (b) effect 
estimates and confidence intervals, 
ideally with a forest plot. 
23-29, 
Table III 
(30-36) 
 
 
 
xviii
 
Section/topic 
 
# 
 
Checklist item 
Reported on 
page # 
Synthesis of results  21 Present results of each meta-analysis 
done, including confidence intervals 
and measures of consistency. 
Not done 
Risk of bias across 
studies 
22 Present results of any assessment of 
risk of bias across studies (see Item 
15). 
21-23 
Additional analysis 23 Give results of additional analyses, if 
done (e.g., sensitivity or subgroup 
analyses, meta-regression [see Item 
16]). 
Not done 
DISCUSSION 
Summary of evidence 24 Summarize the main findings 
including the strength of evidence for 
each main outcome; consider their 
relevance to key groups (e.g., health 
care providers, users, and policy 
makers). 
37-42 
Limitations 25 Discuss limitations at study and 
outcome level (e.g., risk of bias), and 
at review level (e.g., incomplete 
retrieval of identified research, 
reporting bias). 
43-44 
Conclusions 26 Provide a general interpretation of the 
results in the context of other 
44-48 
 
 
 
xix
 
Section/topic 
 
# 
 
Checklist item 
Reported on 
page # 
evidence, and implications for future 
research. 
 
FUNDING 
Funding  27 Describe sources of funding for the 
systematic review and other support 
(e.g., supply of data); role of funders 
for the systematic review. 
xi 
 
